Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate

A. Vecchi, M. Cairo, A. Mantovani, M. Sironi, F. Spreafico

Research output: Contribution to journalArticlepeer-review


A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, i.e., ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalCancer Treatment Reports
Issue number1
Publication statusPublished - 1978

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate'. Together they form a unique fingerprint.

Cite this